Current reports

Warning: simplexml_load_file(): SSL: Connection reset by peer in /usr/home/sniznik/domains/celonpharma.com/public_html/wp-content/themes/celon/category-raporty-biezace.php on line 22 Warning: simplexml_load_file(https://www.gpw.pl/wyniki/a45_u__8c/n_CLN_full_data.html): failed to open stream: HTTP request failed! in /usr/home/sniznik/domains/celonpharma.com/public_html/wp-content/themes/celon/category-raporty-biezace.php on line 22 Warning: simplexml_load_file(): I/O warning : failed to load external entity "https://www.gpw.pl/wyniki/a45_u__8c/n_CLN_full_data.html" in /usr/home/sniznik/domains/celonpharma.com/public_html/wp-content/themes/celon/category-raporty-biezace.php on line 22

Current report No. 22/2022 – Decision of the Central Securities Depository of Poland (KDPW) on assimilation of 5,000 C share actions with the Company’s share in the stock exchange trading

Current report No. 22/2022Date prepared: 18/07/2022Abbreviated name of the issuer: CELON PHARMA S.A.Subject: Decision of the Central Securities Depository of Poland (KDPW) on assimilation of 5,000 C share actions with the Company’s share in the stock exchange tradingLegal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodicalRead more »

Current report 21/2022 – Admission and introduction of 5,000 ordinary C-series bearer shares of the Company to stock exchange trading

Current report No. 21/2022 Date prepared: 15/07/2022 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: Admission and introduction of 5,000 ordinary C-series bearer shares of the Company to stock exchange trading Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Content of the report:Read more »

Current report No. 20/2022 – Summary of subscription of ordinary C-series bearer shares in Celon Pharma S.A. Performed under the 2021 Incentive Program

Current report No. 20/2022 Date prepared: 08/07/2022 Abbreviated name of the issuer: Celon Pharma S.A. Subject: Summary of subscription of ordinary C-series bearer shares in Celon Pharma S.A. performed under the Incentive Program for 2021 Legal basis Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information ContentRead more »

Current report No. 18/2022 – List of shareholders holding at least 5% of the votes at the Ordinary General Meeting of the Company held on June 22, 2022

Current report No. 18/2022 Date prepared: June 23, 2022 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: List of shareholders holding at least 5% of the votes at the Ordinary General Meeting of the Company held on June 22, 2022 Legal basis subs. 70 point 3 of the Act on Public Offering – GeneralRead more »

Current report No. 16/2022 – Resolution of the Ordinary General Meeting of the Company on coverage of loss and payment of the dividend for the financial year 2021

Current report No. 16/2022Date prepared: June 22, 2022Abbreviated name of the issuer: CELON PHARMA S.A.Subject: Resolution of the Ordinary General Meeting of the Company on coverage of loss and payment of the dividend for the financial year 2021Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodicalRead more »

Current report No. 15/2022 – Information on the status of the application to the Food and Drug Administration (FDA) for the granting the Breakthrough Designation to Falkieri (Celon’s esketamine DPI) in treatment-resistant bipolar depression therapy

Date: June 20, 2022, 7:42 AMLegal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information. In relation to the current report No. 10/2022 of April 20, 2022 on the submission of an application to the Food and Drug Administration (FDA) for the granting the Breakthrough Designation to Falkieri (Celon’s esketamineRead more »